To date, most trials investigating SGLT2 inhibitors in patients with HFpEF—such as EMPEROR-Preserved [21] and DELIVER [22]—have excluded patients with significant valvular disease, limiting generalizability to the AS population. Here, SLC5A2 is linked to aortic stenosis.